News
Novo Nordisk’s diabetes drug sales growth slows sharply
Sales of Novo Nordisk’s diabetes drugs including Ozempic slowed to grow at 8 per cent year on year in the first half, down sharply from its rate last year, as the company loses market share to rival Eli Lilly and other makers of copycat drugs.
Hosted on MSN9h
Novo Nordisk Edges Up Premarket As Q2 Wegovy Sales Defy Copycat Threats: Retail Stays Bullish Amid Tariff PressureSales of diabetes drug Ozempic increased to 31.8 billion kroner from 28.88 ... and Zepbound for "weight management" ...
Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition is weighing on sales of its diabetes and obesity treatments Ozempic and Wego ...
Novo Nordisk has abandoned another GLP-1/GIP co-agonist and CB1 receptor as part of a significant pipeline clearout that ...
Shares of Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy, fell in pre-market trading and on the ...
Novo Nordisk underestimated the impact of competition from personalized compounded drugs when providing sales estimates for ...
Levi & Korsinsky is representing the shareholder plaintiff in a suit claiming the Ozempic and Wegovy manufacturer withheld ...
Weston's downgrade still values Novo Nordisk stock above its current share price of $47 and change, however. Moreover, Novo ...
Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic ...
Muscle and strength loss in human aging, also known as sarcopenia, can result in trouble with balance and walking, according ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback